1. Home
  2. KEN vs LQDA Comparison

KEN vs LQDA Comparison

Compare KEN & LQDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Kenon Holdings Ltd.

KEN

Kenon Holdings Ltd.

HOLD

Current Price

$79.32

Market Cap

3.6B

Sector

Utilities

ML Signal

HOLD

LQDA

Liquidia Corporation

HOLD

Current Price

$38.14

Market Cap

3.1B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
KEN
LQDA
Founded
2014
2004
Country
Singapore
United States
Employees
N/A
N/A
Industry
Electric Utilities: Central
Biotechnology: Pharmaceutical Preparations
Sector
Utilities
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.6B
3.1B
IPO Year
N/A
2018

Fundamental Metrics

Financial Performance
Metric
KEN
LQDA
Price
$79.32
$38.14
Analyst Decision
Strong Buy
Analyst Count
0
10
Target Price
N/A
$38.60
AVG Volume (30 Days)
14.6K
1.7M
Earning Date
04-01-2026
03-18-2026
Dividend Yield
6.06%
N/A
EPS Growth
177.70
N/A
EPS
8.96
N/A
Revenue
$803,304,000.00
$69,216,000.00
Revenue This Year
N/A
$993.31
Revenue Next Year
N/A
$219.14
P/E Ratio
$8.54
N/A
Revenue Growth
8.15
343.41
52 Week Low
$27.10
$11.26
52 Week High
$79.48
$46.67

Technical Indicators

Market Signals
Indicator
KEN
LQDA
Relative Strength Index (RSI) 67.62 49.29
Support Level $71.30 $38.88
Resistance Level $79.48 $40.95
Average True Range (ATR) 1.69 2.30
MACD 0.27 -0.76
Stochastic Oscillator 87.18 11.23

Price Performance

Historical Comparison
KEN
LQDA

About KEN Kenon Holdings Ltd.

Kenon Holdings Ltd is a holding company that operates dynamic, growth-oriented businesses. The company's operating segments include OPC Power Plants, CPV Group, and ZIM. It generates maximum revenue from the OPC Power Plants segment, which generates and supplies electricity and energy in Israel. CPV Group is a limited partnership owned by OPC, which generates and supplies electricity and energy in the United States. Geographically, the company generates a majority of its revenue from Israel and the rest from the United States.

About LQDA Liquidia Corporation

Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also generates revenue from the sale of Treprostinil Injection through an agreement between its subsidiary and the manufacturer.

Share on Social Networks: